CAS Number 263251-78-1 ChemSpider 7984131 Molar mass 580.5445 g/mol | ATC code None PubChem CID 9808372 Formula C24H32N6O11 | |
 | ||
Tavilermide (INN) (developmental code name MIM-D3) is a selective, small-molecule partial agonist of TrkA, or a nerve growth factor (NGF) mimetic. It is under development by Mimetogen Pharmaceuticals as an ophthalmic (eye drop) solution for the treatment of dry eyes, and is in phase III clinical trials for this indication. Tavilermide is currently being evaluated in two multi-center phase III clinical studies in the United States for the treatment of dry eye disease.[1] Tavilermide is also in phase I clinical trials for the treatment of glaucoma; studies are ongoing.
References
Tavilermide Wikipedia(Text) CC BY-SA